NEW ORLEANS--(BUSINESS WIRE)--Pfizer announced today that Lipitor® (atorvastatin calcium) Tablets 10 mg provided a significant 61 percent reduction in stroke in patients with type 2 diabetes and metabolic syndrome but without heart disease. In a separate study, patients who had suffered a recurrent stroke or mini-stroke during the trial had a significant 53 percent reduction in the risk of major coronary events (death from cardiac causes, heart attack, or resuscitation after cardiac arrest) with Lipitor 80 mg. These analyses from two landmark clinical outcomes studies were presented at the annual meeting of the American College of Cardiology.
